1. Home
  2. ACRS vs LXFR Comparison

ACRS vs LXFR Comparison

Compare ACRS & LXFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$2.65

Market Cap

314.2M

Sector

Health Care

ML Signal

HOLD

Logo Luxfer Holdings PLC

LXFR

Luxfer Holdings PLC

HOLD

Current Price

$13.96

Market Cap

376.0M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRS
LXFR
Founded
2012
1898
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
314.2M
376.0M
IPO Year
2015
2012

Fundamental Metrics

Financial Performance
Metric
ACRS
LXFR
Price
$2.65
$13.96
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$9.75
N/A
AVG Volume (30 Days)
1.2M
110.1K
Earning Date
11-06-2025
02-24-2026
Dividend Yield
N/A
3.76%
EPS Growth
N/A
55.43
EPS
N/A
0.53
Revenue
$15,742,000.00
$397,300,000.00
Revenue This Year
N/A
$0.62
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$26.23
Revenue Growth
N/A
3.36
52 Week Low
$1.05
$9.41
52 Week High
$3.48
$14.96

Technical Indicators

Market Signals
Indicator
ACRS
LXFR
Relative Strength Index (RSI) 41.24 62.93
Support Level $2.88 $13.49
Resistance Level $3.04 $14.08
Average True Range (ATR) 0.18 0.30
MACD -0.07 -0.04
Stochastic Oscillator 20.12 76.19

Price Performance

Historical Comparison
ACRS
LXFR

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About LXFR Luxfer Holdings PLC

Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.

Share on Social Networks: